JP2012515170A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515170A5 JP2012515170A5 JP2011545542A JP2011545542A JP2012515170A5 JP 2012515170 A5 JP2012515170 A5 JP 2012515170A5 JP 2011545542 A JP2011545542 A JP 2011545542A JP 2011545542 A JP2011545542 A JP 2011545542A JP 2012515170 A5 JP2012515170 A5 JP 2012515170A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- prg4
- androgen
- vaginal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 102100006119 PLPPR2 Human genes 0.000 claims 10
- 101710027973 PLPPR2 Proteins 0.000 claims 10
- 101700020998 PRG4 Proteins 0.000 claims 10
- 239000003098 androgen Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 238000005461 lubrication Methods 0.000 claims 5
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 229920002674 hyaluronan Polymers 0.000 claims 3
- 229960003160 hyaluronic acid Drugs 0.000 claims 3
- 229940010747 Sodium Hyaluronate Drugs 0.000 claims 2
- 229920002385 Sodium hyaluronate Polymers 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 230000003110 anti-inflammatory Effects 0.000 claims 2
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 2
- 230000003247 decreasing Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002757 inflammatory Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000009245 menopause Effects 0.000 claims 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 2
- 230000001568 sexual Effects 0.000 claims 2
- 230000002459 sustained Effects 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- ZCDMRPMKAQLWAO-PZLFCYFRSA-N (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid;(9Z,12Z)-octadeca-9,12-dienoic acid Chemical class CCCCC\C=C/C\C=C/CCCCCCCC(O)=O.CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O ZCDMRPMKAQLWAO-PZLFCYFRSA-N 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- 150000000319 19-nortestosterones Chemical class 0.000 claims 1
- QUKZBUCPOSYYFO-KYQPOWKGSA-N 5α-Androstan-17β-ol Chemical class C1CCC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 QUKZBUCPOSYYFO-KYQPOWKGSA-N 0.000 claims 1
- 206010002261 Androgen deficiency Diseases 0.000 claims 1
- 206010059313 Anogenital warts Diseases 0.000 claims 1
- 229940046844 Aromatase inhibitors Drugs 0.000 claims 1
- 229960005261 Aspartic Acid Drugs 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 206010007134 Candida infection Diseases 0.000 claims 1
- 208000010247 Contact Dermatitis Diseases 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000006922 Drug-Related Side Effects and Adverse Reaction Diseases 0.000 claims 1
- 229960005309 Estradiol Drugs 0.000 claims 1
- 229940011871 Estrogens Drugs 0.000 claims 1
- 229940028334 Follicle Stimulating Hormone Drugs 0.000 claims 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 1
- 210000004392 Genitalia Anatomy 0.000 claims 1
- 229940088597 Hormone Drugs 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000019223 Interleukin-1 receptor family Human genes 0.000 claims 1
- 108050006617 Interleukin-1 receptor family Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline zwitterion Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 1
- 206010030247 Oestrogen deficiency Diseases 0.000 claims 1
- 229940012843 Omega-3 Fatty Acids Drugs 0.000 claims 1
- 229940033080 Omega-6 Fatty Acids Drugs 0.000 claims 1
- 210000001672 Ovary Anatomy 0.000 claims 1
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical class C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 claims 1
- 206010036601 Premature menopause Diseases 0.000 claims 1
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 claims 1
- 229940030484 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Drugs 0.000 claims 1
- 229940095743 Selective estrogen receptor modulators Drugs 0.000 claims 1
- 206010040767 Sjogren's syndrome Diseases 0.000 claims 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 1
- 206010062167 Vaginitis bacterial Diseases 0.000 claims 1
- 208000003728 Vulvodynia Diseases 0.000 claims 1
- 206010069055 Vulvovaginal pain Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims 1
- 230000001548 androgenic Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 239000003855 balanced salt solution Substances 0.000 claims 1
- -1 bicyclic hydantoin analog Chemical class 0.000 claims 1
- 201000003984 candidiasis Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- 235000013477 citrulline Nutrition 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 231100000080 dermatitis contact Toxicity 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229940046080 endocrine therapy drugs Estrogens Drugs 0.000 claims 1
- 239000003687 estradiol congener Substances 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 238000009164 estrogen replacement therapy Methods 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000006651 lactation Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000001264 neutralization Effects 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 239000006014 omega-3 oil Substances 0.000 claims 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims 1
- 230000003204 osmotic Effects 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 201000000926 premature ovarian failure Diseases 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000002829 reduced Effects 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 1
- 150000003515 testosterones Chemical class 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
Claims (15)
- 膣境界潤滑低下又はそれに関連する疾患の治療を必要とする被験者の膣表面に、治療上有効量、局所投与される医薬組成物であり、膣境界潤滑低下又はそれに関連する疾患の治療に用いるための医薬組成物であって、
当該医薬組成物は、単離又は組み換えPRG4又はそれらのフラグメント及び製薬上許容される担体を含み、前記単離又は組み換えPRG4は、膣境界潤滑を改善するのに十分であり、場合によっては、前記組成物は、ゲル、浸透圧平衡塩類水溶液、多相エマルション、または徐放性もしくは持続放出性製剤に製剤されている、医薬組成物。 - アンドロゲンもしくはアンドロゲン類似体、選択的アンドロゲン受容体調節剤、選択的エストロゲン受容体調節剤、エストロゲンアンタゴニスト、アロマターゼ阻害剤、アンチプロテアーゼ、炎症性サイトカインアンタゴニスト、サイトカイン放出阻害剤、抗炎症性サイトカイン、抗炎症薬、NF−κB阻害剤、プロテアソーム阻害剤、ヒアルロン酸、中性もしくは極性脂質、脂肪酸、エストロゲンもしくはエストロゲン類似体、エストラジオール、プロゲステロン、卵胞刺激ホルモン、黄体形成ホルモン、ヒアルロン酸ナトリウム、ヒアルロン酸、酸化窒素、及びアミノ酸からなる群より選択される治療薬をさらに含有する、請求項1に記載の医薬組成物。
- 前記アンドロゲン、又はアンドロゲン類似体が、17α−メチル−17β−ヒドロキシ−2−オキサ−5α−アンドロスタン−3−オン誘導体、テストステロン誘導体、4,5α−ジヒドロテストステロン誘導体、環A不飽和を含む17β−ヒドロキシ−5α−アンドロスタン誘導体、19−ノルテストステロン誘導体、窒素置換アンドロゲン、異常な構造特徴を有するアンドロゲン化合物を含むアンドロゲンの構造サブクラス、またはそれらの組合せである、請求項2に記載の医薬組成物。
- 前記選択的アンドロゲン受容体調節剤がアリール−プロピオンアミド化合物、二環式ヒダントイン類似体、キノリン類似体、またはテトラヒドロキノリン類似である、請求項2に記載の医薬組成物。
- 前記炎症性サイトカインアンタゴニストが、抗TNFα抗体、可溶性TNFα受容体、およびIL−1受容体アンタゴニストから成る群より選択される、請求項2に記載の医薬組成物。
- 前記抗炎症薬が、シクロスポリンA、ならびにω3脂肪酸およびω6脂肪酸から成る群より選択される、請求項2に記載の医薬組成物。
- 組成物が10〜100,000μg/mL又は500〜5,000μg/mLの濃度のヒアルロン酸ナトリウムまたはヒアルロン酸を含有する、請求項2に記載の医薬組成物。
- 組成物が10〜10,000μg/mLの濃度のPRG4を含有する、請求項1に記載の医薬組成物。
- PRG4が50kDa〜400kDaの平均モル質量を有する、請求項1に記載の医薬組成物。
- PRG4が、その潤滑性フラグメント、多量体またはホモログを含む、請求項1に記載の医薬組成物。
- PRG4が、組換えPRG4タンパク質、単離PRG4タンパク質またはその機能的フラグメントである、請求項1に記載の医薬組成物。
- PRG4又はそれらのフラグメントが、配列番号:1と少なくとも75%一致しているアミノ酸配列を含む、請求項1に記載の医薬組成物。
- 前記アミノ酸が、L−アルギニン、シトルリン又はアスパラギン酸である、請求項2に記載の医薬組成物。
- 膣境界潤滑の低下に関連する疾患が、膣萎縮症、性交疼痛症、シェーグレン症候群、更年期障害、アンドロゲン欠損症、エストロゲン欠損症、エストロゲン補充療法、アレルギー、慢性炎症、閉経、早発閉経、化学療法、授乳、閉経前の卵巣の外科的切除、生殖器硬化性萎縮性苔癬、外陰部痛、細菌性膣炎、疱疹、カンジダ症、乾癬、接触皮膚炎、コンジローム、又は薬剤の副作用および加齢である、請求項1に記載の医薬組成物。
- 有効量の単離または精製PRG4又は請求項1〜14のいずれか一項に記載の医薬組成物を、膣表面、陰茎表面またはその組合せに局所投与することを含む、性交の間の潤滑又は受胎促進を提供する方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14434409P | 2009-01-13 | 2009-01-13 | |
US61/144,344 | 2009-01-13 | ||
US26040209P | 2009-11-12 | 2009-11-12 | |
US61/260,402 | 2009-11-12 | ||
PCT/US2010/020929 WO2010083239A2 (en) | 2009-01-13 | 2010-01-13 | Therapeutic modulation of vaginal epithelium boundary lubrication |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015062261A Division JP6039723B2 (ja) | 2009-01-13 | 2015-03-25 | 膣上皮境界潤滑の治療的調節 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012515170A JP2012515170A (ja) | 2012-07-05 |
JP2012515170A5 true JP2012515170A5 (ja) | 2012-09-13 |
Family
ID=42340279
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011545542A Pending JP2012515170A (ja) | 2009-01-13 | 2010-01-13 | 膣上皮境界潤滑の治療的調節 |
JP2015062261A Expired - Fee Related JP6039723B2 (ja) | 2009-01-13 | 2015-03-25 | 膣上皮境界潤滑の治療的調節 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015062261A Expired - Fee Related JP6039723B2 (ja) | 2009-01-13 | 2015-03-25 | 膣上皮境界潤滑の治療的調節 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8980840B2 (ja) |
EP (1) | EP2381957B1 (ja) |
JP (2) | JP2012515170A (ja) |
CN (1) | CN102438645A (ja) |
CA (1) | CA2749480C (ja) |
ES (1) | ES2534082T3 (ja) |
WO (1) | WO2010083239A2 (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007045027A1 (en) | 2005-10-19 | 2007-04-26 | Chavah Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
US8980840B2 (en) * | 2009-01-13 | 2015-03-17 | Schepens Eye Research Institute | Therapeutic modulation of vaginal epithelium boundary lubrication |
US9730865B2 (en) | 2009-05-22 | 2017-08-15 | Lubris, Llc | Application and uses of PRG4 and therapeutic modulation thereof |
CA2771110C (en) * | 2009-08-13 | 2019-02-26 | Singularis, Inc. | Prg4 treatment for interstitial cystitis |
CN102552996A (zh) * | 2010-12-07 | 2012-07-11 | 宁小静 | 人体润滑剂 |
ES2395801B1 (es) * | 2011-06-23 | 2014-06-06 | María Carmen PARDINA PALLEJÀ | "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad" |
ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
WO2015060935A1 (en) | 2013-10-22 | 2015-04-30 | Lubris, Llc | Control of rheological properties of mixed hyaluronate/lubricin solutions |
US10500250B2 (en) | 2013-11-26 | 2019-12-10 | Lubris Llc | Compositions and methods for inhibiting intercellular interactions |
RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
JP2017523138A (ja) | 2014-07-29 | 2017-08-17 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 経皮クリーム |
JP2017531685A (ja) | 2014-10-22 | 2017-10-26 | ハバフ セラピューティクス ピーティーワイ エルティーディー | マンモグラフィ乳房密度及び/又は乳癌リスクを低下させる方法 |
EP3718559A1 (en) * | 2015-01-26 | 2020-10-07 | Lubris LLC | Use of prg4 as an anti-inflammatory agent |
SI3300482T1 (sl) | 2015-05-19 | 2021-11-30 | Lubris Llc | Uporaba prg4 za izboljšanje dinamične ostrine vide in aberacij višjega reda |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
SG11201803260PA (en) | 2015-10-22 | 2018-05-30 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US11524014B2 (en) | 2019-06-03 | 2022-12-13 | Havah Therapeutics Pty Ltd. | Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor with sustained multi-phasic release profiles and methods of use |
WO2023042216A1 (en) * | 2021-09-15 | 2023-03-23 | Chemex Global | Topical pharmaceutical compositions for treatment of infertility |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3005A (en) * | 1843-03-17 | Power-loom | ||
US7027A (en) * | 1850-01-15 | Circulak | ||
US7000A (en) * | 1850-01-08 | Smut-machine | ||
US6433142B1 (en) | 1989-08-08 | 2002-08-13 | Genetics Institute, Llc | Megakaryocyte stimulating factors |
US5326558A (en) | 1989-08-08 | 1994-07-05 | Genetics Institute, Inc. | Megakaryocytopoietic factor |
EP1027057A4 (en) * | 1997-10-28 | 2003-01-02 | Vivus Inc | TREATMENT OF FEMALE SEXUAL DISORDERS |
US6960562B2 (en) | 1999-04-23 | 2005-11-01 | Rhode Island Hospital, A Lifespan Partner | Tribonectin polypeptides and uses thereof |
US6743774B1 (en) | 1999-04-23 | 2004-06-01 | Rhode Island Hospital | Tribonectins |
US6335023B1 (en) | 1999-06-30 | 2002-01-01 | Ruey J. Yu | Oligosaccharide aldonic acids and their topical use |
US7452545B2 (en) | 2001-11-13 | 2008-11-18 | Yu Ruey J | Oligosaccharide aldonic acids and their topical use |
US20030059489A1 (en) | 2001-09-24 | 2003-03-27 | Canolio Inc. | Genital lubricating compositions and uses thereof |
US7005408B2 (en) * | 2002-05-01 | 2006-02-28 | Mcneil-Ppc, Inc. | Warming and nonirritating lubricant compositions and method of comparing irritation |
US20060240037A1 (en) * | 2003-06-04 | 2006-10-26 | Edward Fey | Methods and compositions for the treatment and prevention of degenerative joint disorders |
MXPA06001658A (es) * | 2003-08-14 | 2006-04-28 | Wyeth Corp | Moleculas de lubricina recombinantes y usos de las mismas. |
US7405303B2 (en) * | 2004-02-25 | 2008-07-29 | Smithkline Beecham Corporation | Substituted quinoline compounds for use as selective estrogen receptor modulator |
US20070275032A1 (en) * | 2004-03-05 | 2007-11-29 | Synthes (U.S.A.) | Use Of A Mixture For The Production Of An Agent For Treating Defective Or Degenerated Cartilage In The Production Of Natural Cartilage Replacement In Vitro |
US8703198B2 (en) * | 2005-03-02 | 2014-04-22 | Aquatrove Biosciences | Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof |
US10016442B2 (en) | 2005-06-16 | 2018-07-10 | Allergan Pharmaceuticals International Limited | Estrogen compositions for vaginal administration |
EP1890704A1 (en) * | 2005-12-16 | 2008-02-27 | Lyle Corporate Development, Inc. | Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen |
CN101405006A (zh) * | 2006-01-20 | 2009-04-08 | 梨树医药公司 | 治疗萎缩性阴道炎的方法 |
WO2008133928A2 (en) * | 2007-04-27 | 2008-11-06 | The Gi Company, Inc. | Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders |
WO2008143816A1 (en) * | 2007-05-15 | 2008-11-27 | Mucosal Therapeutics | Compositions and methods for reducing friction between the surface of tendons or other soft tissues |
GB0722507D0 (en) * | 2007-11-19 | 2007-12-27 | Zhao Xiaobin | Hyaluronic acid personal lubricant |
US8980840B2 (en) * | 2009-01-13 | 2015-03-17 | Schepens Eye Research Institute | Therapeutic modulation of vaginal epithelium boundary lubrication |
-
2010
- 2010-01-13 US US13/144,203 patent/US8980840B2/en active Active
- 2010-01-13 JP JP2011545542A patent/JP2012515170A/ja active Pending
- 2010-01-13 WO PCT/US2010/020929 patent/WO2010083239A2/en active Application Filing
- 2010-01-13 ES ES10732051.7T patent/ES2534082T3/es active Active
- 2010-01-13 EP EP10732051.7A patent/EP2381957B1/en active Active
- 2010-01-13 CN CN2010800112543A patent/CN102438645A/zh active Pending
- 2010-01-13 CA CA2749480A patent/CA2749480C/en active Active
-
2015
- 2015-03-25 JP JP2015062261A patent/JP6039723B2/ja not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012515170A5 (ja) | ||
CA2749480A1 (en) | Therapeutic modulation of vaginal epithelium boundary lubrication | |
ES2586122T3 (es) | Formulaciones de testosterona | |
JP2023002662A5 (ja) | ||
US20160136231A1 (en) | Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions | |
AU2001285367B2 (en) | Method of increasing testosterone and related steroid concentrations in women | |
ES2338782T3 (es) | Composicion farmaceutica oral que comprende 15-hidroxitestosterona y derivados. | |
HRP20110801T1 (hr) | Tekući oblik fsh | |
TWI746613B (zh) | 子宮內膜病症治療劑之用法及用量 | |
KR20120107492A (ko) | 프로게스틴/에스트라디올 경피 젤 | |
EP2283865A1 (en) | Method of increasing testosterone and related steroid concentrations in women | |
JP2013542190A5 (ja) | ||
KR20090080989A (ko) | 여성 리비도의 유지 및/또는 증가를 위한 경구 치료요법을 위한 디에노게스트와 조합된 에스트라디올 발레레이트 또는 17β-에스트라디올의 용도 | |
KR20110045004A (ko) | 충혈제거제 및 코르티코스테로이드를 포함하는 비강내 조성물 | |
US20030181384A1 (en) | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions | |
JP2020500864A5 (ja) | ||
CR6627A (es) | Nuevo medicamento contraceptivo y su modo de preparacion | |
JP2017514851A5 (ja) | ||
RU2011108548A (ru) | Лечение вагинальной атрофии у женщин с риском опухолевой патологии | |
US20160022644A1 (en) | Oral Transmucosal Compositions Including Aromatase Inhibitors for Treating Female Infertility | |
US9452174B2 (en) | Oral transmucosal pharmaceutical compositions including testosterone and a C-SERM | |
US10213440B2 (en) | Oral transmucosal pharmaceutical compositions including testosterone and an aromatase inhibitor | |
US20170165197A1 (en) | Dermatological stick comprising plant extracts, methods and uses thereof | |
US20160051496A1 (en) | Oral Transmucosal Compositions Including C-SERMs for Treating Female Infertility | |
ITMI20121917A1 (it) | Composizioni per uso vaginale comprendenti polisaccaridi da tamarindo |